Abstract
We herein report a case of a drug eruption suspected to be caused by SGLT2 inhibitors in a patient with type 2 diabetes. The patient was a 63-year-old woman who had been treated with sitagliptin and glimepiride. Her HbA1c level had been approximately 8 %; therefore, luseogliflozin was added to her regimen. On the eighth day of luseogliflozin treatment, she developed erythema on her neck, which later spread to her limbs and trunk. Neither the cessation of luseogliflozin treatment nor administration of steroids by a local physician improved her symptoms, and she was subsequently admitted to our hospital. A dermatologist suspected that luseogliflozin had caused the drug eruption. Consequently, the patient was treated with intravenous prednisolone at a dose of 40 mg per day, which improved the erythema. She was discharged after the steroid dose was gradually reduced (the oral prednisolone dose was tapered to 10 mg per day). Based on the patient's clinical course and biopsy results, the drug eruption was suspected to have been caused by luseogliflozin. Therefore, it is important to inform patients that they should be examined by a dermatologist as soon as possible if they develop a skin rash after taking SGLT2 inhibitors.
